Source comparison
MK-677 Perimenopause Research Mechanism: Comparison Table
MK-677 25mg daily GH-IGF-1 axis GHSR-1a agonism → pulsatile GH release → hepatic IGF-1 synthesis +1.8% BMD (lumbar spine, postmenopausal women, placebo-controlled) +1.1 kg lean body mass vs placebo (elderly cohort) +50–84% SWS duration within 1 week Addresses
This comparison does not assign a generated winner or score.
- MK-677 25mg daily
- GH-IGF-1 axis
- GHSR-1a agonism → pulsatile GH release → hepatic IGF-1 synthesis
- +1.8% BMD (lumbar spine, postmenopausal women, placebo-controlled)
- +1.1 kg lean body mass vs placebo (elderly cohort)
- +50–84% SWS duration within 1 week
- Addresses downstream metabolic consequences of estrogen loss without hormone replacement. Strongest effect on sleep and anabolic signaling
- Estradiol HRT (standard dose)
- Estrogen receptors (ERα/ERβ)
- Direct estrogen receptor binding in bone, brain, vasculature
- +2.5–4% BMD (varies by dose/formulation)
- Modest preservation vs decline without HRT
- Improves hot flashes but limited direct sleep architecture effect
- Gold standard for vasomotor symptoms and bone. Does not restore GH-IGF-1 axis
- Resistance training (3x/week)
- Mechanical loading pathways
- mTOR activation via mechanical tension, localized IGF-1 expression
- +1–2% site-specific BMD (loading-dependent)
- +2–4 kg lean mass over 6–12 months (effort-dependent)
- Improves sleep latency but not SWS consolidation
- Most cost-effective anabolic stimulus. Requires adherence and progressive overload
- Selective estrogen receptor modulators (SERMs)
- Tissue-selective ER binding
- Agonism in bone, antagonism in breast/uterine tissue
- +1.5–2.8% BMD (raloxifene data)
- Neutral to slightly negative lean mass effect
- No direct sleep benefit
- Bone-protective without systemic estrogen exposure. Does not address muscle or metabolic function